Safe ketone levels with dapagliflozin for type 1 diabetes
Treatments studied
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This study tests whether a medication called dapagliflozin (a type of SGLT2 inhibitor) can be used safely in people with type 1 diabetes by checking blood ketone levels. It may help find a way to lower the risk of a serious condition called ketoacidosis while using this medication.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 24 and 85 years old.
- You must have had type 1 diabetes for at least 1 year.
- You must take at least 0.4 units of insulin per kilogram of body weight each day.
- You must not have had diabetic ketoacidosis (DKA) in the last year.
- You must eat at least 100 grams of carbohydrates every day (no strict low-carb diet).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a dual continuous ketone and glucose monitor to help prevent diabetic ketoacidosis (DKA) in people with type 1 diabetes who are starting SGLT2 inhibitor treatment. SGLT2 inhibitors are a newer type of diabetes medicine, but they can increase the risk of DKA. The device may make using these medicines safer.
This study tests if dapagliflozin (a medication for diabetes and kidney health) can help prevent kidney injury in people with type 1 diabetes. It is for adults aged 18 to 64 who have moderately reduced kidney function and some protein in their urine.
This trial tests how two diabetes medications, SGLT2i and pioglitazone, affect ketone production in people with type 1 diabetes. It aims to find new ways to improve blood sugar control.
This trial tests how combining a ketone supplement with certain diabetes medicines affects blood sugar and ketone levels. It may help adults with type 2 diabetes who are not on insulin or certain other drugs.
This trial tests if a drug called dapagliflozin (an SGLT2 inhibitor) can help prevent complications in people with prediabetes when added to lifestyle changes. It aims to see if this approach works better than lifestyle changes alone.
This study tests a device that monitors ketone levels to help reduce the risk of diabetic ketoacidosis (DKA) for people with type 1 diabetes who are taking a class of medications called SGLT-2 inhibitors. The goal is to see if regular ketone tracking can make these medications safer.
Hear when a new Type 1 Diabetes Mellitus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.